| HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status | 07/03 20:00 | globenewswire.com |
| HUTCHMED to Announce 2024 Half-Year Financial Results | 06/26 04:30 | globenewswire.com |
| HCM Digital World Class Matrix™ Identifies Software Innovations and Leading Providers | 06/25 10:54 | businesswire.com |
| Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 | 06/24 05:30 | globenewswire.com |
| HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda | 06/21 16:00 | globenewswire.com |
| HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology | 06/16 20:00 | globenewswire.com |
| HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China | 06/06 20:00 | globenewswire.com |
| HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine | 06/02 20:00 | globenewswire.com |
| HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting | 05/23 20:00 | globenewswire.com |
| Paycom: Initiating Buy On Strong Growth Tailwind And BETI Pricing Power | 05/20 22:34 | seekingalpha.com |